Add-on therapy with montelukast or formoterol in patients with the glycine-16 β2-receptor genotype

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 104-111

  Sims, Erika J ^a   Jackson, Catherine M ^b   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

2 agonists; Adenosine monophosphate; Asthma; Formoterol; Genetics; Leukotriene antagonists; Montelukast; Polymorphism

Indexed keywords

ADENOSINE PHOSPHATE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; GLYCINE; IPRATROPIUM BROMIDE; MONTELUKAST; PLACEBO;

ADD ON THERAPY; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DOWN REGULATION; EOSINOPHIL; FEMALE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT OUTCOME;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HUMANS; PEAK EXPIRATORY FLOW RATE; QUINOLINES; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0038336619     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01899.x     Document Type: Article

References (45)

1. British Thoracic Society. The British Guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-S21.
2. National Asthma Education and Prevention Program Expert Panel Report. Guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 2002; 110 (2): S141-S219.
3. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
4. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373.
5. Aziz I, Tan KS, Hall IP et al. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once daily formoterol. Eur Respir J 1998; 12: 580-584.
6. Grove A, Lipworth BJ. Bronchodilator subsensitivity to inhaled salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-216.
7. Kalra S, Swystun VA, Bhagat R et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956.
8. Lipworth B, Tan S, Devlin M et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104: 431-438.
9. Tan KS, Grove A, McLean A et al. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997; 156: 28-35.
10. Green SA, Turki J, Innis M et al. Amino-terminal polymorphisms of the human beta-adrenergic receptor impart distinct agonist-promotive regulatory properties. Biochemistry 1994; 33: 414-419.
11. Green SA, Turki J, Vegarno P et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airways smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25-33.
12. Tan KS, Hall IP, Dewar J et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995-999.
13. Martinez FD, Graves PE, Baldini M et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-3188.
14. Lima JJ, Thomason DB, Mohamed MH et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65: 519-525.
15. Taylor DR, Drazen JM, Herbison GP et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55: 762-767.
16. Israel E, Drazen JM, Liggett SB et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75-80.
17. Dewar JC, Wheatley AP, Venn A et al. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 1998; 28: 442-448.
18. Fowler SJ, Dempsey OJ, Sims EJ et al. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta(2)-receptor genotype. Am J Respir Crit Care Med 2000; 162: 1318-1322.
19. Lipworth BJ. Leukotriene-receptor antagonists Lancet 1999; 353: 57-62.
20. Laviolette M, Malmstrom K, Lu S et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160: 1862-1868.
21. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155: 1235-1240.
22. Lofdahl C, Reiss TF, Leff JA et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
23. Lee DKC, Gray RD, Lipworth BJ. Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clin Exper Allergy 2003; 33: 287-294.
24. O'Connor BJ, Ridge SM, Barnes PJ et al. Greater effect of inhaled budesonide on adenosine 5′-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Respir Dis 1992; 146: 560-564.
25. Wilson AM, Lipworth BJ. Dose-response evaluation of the therapeutic index for inhaled budesonide in mild to moderate atopic asthmatic patients. Am J Med 2000; 108: 269-275.
26. Van Den Berge M, Kerstjens HA, Meijer RJ et al. Corticosteroid-induced improvement in the PC (20) of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC (20) of methacholine. Am J Respir Crit Care Med 2001; 164: 1127-1132.
27. Nightingale JA, Rogers DF, Barnes PJ. Differential effects of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med 1999; 159: 1786-1790.
28. Bousquet J, Corrigan CJ, Venge P. Peripheral blood markers: evaluation of inflammation in asthma. Eur Respir J 1998; 26: 42S-48S.
29. Wilson AM, Dempsey OJ, Sims EJ et al. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31: 616-624.
30. Tan KS, McFarlane LC, Lipworth BJ. Loss of normal cyclical beta 2-adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatics. Thorax 1997; 52: 608-611.
31. Kharitonov SA, Chung KF, Evans DJ et al. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996; 153: 1773-1780.
32. Byrnes CA, Dinarevic S, Busst CA et al. Effect of measurement conditions on measured levels of peak exhaled nitric oxide. Thorax 1997; 52: 697-701.
33. American Thoracic Society. Standardisation of spirometry - update. Am Rev Respir Dis 1987; 136: 1285-1298.
34. Wilson AM, Dempsey OJ, Sims EJ et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119: 1021-1026.
35. Villaran C, O'Neill SJ, Helbling A et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999; 104: 547-553.
36. Edellman JM, Turpin JA, Bronsky EA et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern Med 2000; 132: 97-104.
37. 2-adrenoceptor genotype. Am J Med 2000; 109: 114-121.
38. O'Connor BJ, Aikman S, Barnes PJ. Tolerance to the non-bronchodilator effects of inhaled beta-2 agonists in asthma. N Engl J Med 1992; 327: 1204-1208.
39. 2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000; 105: 487-492.
40. Drysdale CMI, McGraw DW, Stuck CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97: 10483-10488.
41. Bisgaard H, Loland L, Anhoj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160: 1227-1231.
42. Fish JE, Israel E, Murray JJ et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423-430.
43. Busse WW, Nelson HS, Wolfe J et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075-1080.
44. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-1095.
45. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomized double-blind placebo-controlled trial. Lancet 2001; 357: 2007-2011.